Three cases of noninvasive encapsulated papillary RAS-like (NEPRAS) thyroid tumor are reported in this issue \[[@b1-jptm-2020-04-29]\]. The term "NEPRAS" was first used by Ohba et al. in 2019 \[[@b2-jptm-2020-04-29]\] to designate a noninvasive thyroid tumor showing a complete fibrous capsule, a predominantly papillary architecture, and RAS mutation but with subtle nuclear features of papillary thyroid carcinoma (PTC) ([Fig. 1](#f1-jptm-2020-04-29){ref-type="fig"}). The tumor was considered a borderline thyroid tumor that showed a predominantly papillary structure. The name and concept of "NEPRAS" tumors were proposed as a counterpart of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) having a predominantly follicular architecture. NEPRAS is different from follicular adenoma with papillary hyperplasia because of the appearance of nuclear features of PTC ([Fig. 2](#f2-jptm-2020-04-29){ref-type="fig"}). The distinction between NEPRAS and NIFTP is based on the presence of papillary structure in NEPRAS tumors ([Table 1](#t1-jptm-2020-04-29){ref-type="table"}). NEPRAS tumors with *RAS* mutations or other *RAS*-like mutations are different from encapsulated classic PTCs in that classic PTCs typically harbor the *BRAF* V600E mutation. Therefore, in the diagnostic schema recommended by the World Health Organization (WHO) classification of thyroid tumors, pathologists might have variably classified these noninvasive encapsulated tumors as either benign follicular adenoma or encapsulated PTC depending on the subjective judgment of nuclear features.

The 2017 WHO classification newly adopted a borderline tumor of the thyroid \[[@b3-jptm-2020-04-29]\]. Encapsulated follicular-patterned thyroid tumors with borderline behavior include follicular tumor of uncertain malignant potential (FT-UMP), well-differentiated tumor of uncertain malignant potential (WDT-UMP), and NIFTP \[[@b3-jptm-2020-04-29]\]. FT-UMP has round nuclei that lack PTC-type nuclear features, whereas WDT-UMP and NIFTP share the nuclear features of PTC, including a nuclear score of 2 or 3 on a three-point scoring scale \[[@b3-jptm-2020-04-29]\]. Although encapsulated follicularpatterned lesions are well defined by the WHO classification, there is a lack of consensus on encapsulated papillary-patterned thyroid tumors that demonstrate subtle nuclear changes. Many diagnostically controversial cases exhibit subtle nuclear features, such as a nuclear score of 2, and therefore pose challenges for accurate diagnosis.

Pathologic diagnosis of a thyroid tumor is fundamentally dependent on pathologists' knowledge and experience in interpreting microscopic findings \[[@b4-jptm-2020-04-29]-[@b8-jptm-2020-04-29]\]. Due to variable application of loose or strict criteria in assessing the nuclear features of PTC and its invasion of the tumor capsule and vessels, there is discrepancy in diagnosis of encapsulated/well-circumscribed thyroid tumors among pathologists \[[@b6-jptm-2020-04-29]-[@b9-jptm-2020-04-29]\]. Noninvasive encapsulated papillary-patterned thyroid tumor is diagnosed as encapsulated classic PTC if nuclear features of the tumor are interpreted as nuclear score of 3. However, diagnostic challenges may arise in cases with subtle nuclear changes. In Western practice, equivocal nuclear changes are more easily interpreted as PTC-type nuclear features, whereas most Asian pathologists agree that such nuclear features are insufficient for diagnosis of PTC \[[@b10-jptm-2020-04-29]\]. As a result, the same tumor can be diagnosed as a follicular adenoma by certain pathologists who apply more stringent criteria for diagnosis of PTC.

*RAS*-mutated thyroid tumors demonstrate different histology and biological behavior than tumors with *BRAF* V600E mutation \[[@b11-jptm-2020-04-29]\]. *RAS* or other *RAS*-like mutations are frequently found in follicular adenoma, NIFTP, and follicular carcinoma with a similarity in the possible spectrum of mutations \[[@b12-jptm-2020-04-29]-[@b14-jptm-2020-04-29]\]. In PTCs, two molecular subtypes, *BRAF* V600E-like and *RAS*-like types, were proposed by the Cancer Genome Atlas (TCGA) project \[[@b11-jptm-2020-04-29]\]. Follicular-patterned PTCs typically carry *RAS*-like mutations, including *RAS* mutations, whereas PTCs with papillary architecture have *BRAF* V600E or other *BRAF*-like mutations. However, this rule does not apply in all cases. *RAS*-like mutations can be found in PTCs with papillary architecture. In the TCGA dataset \[[@b11-jptm-2020-04-29]\], of 250 classic PTCs with molecular classification data, 43 (17.2%) had an *RAS*-like molecular signature, while 16 (6.3%) had *RAS* mutations. Noninvasive encapsulated papillary-patterned tumor can also demonstrate PTC-like nuclear features and *RAS* mutations. The tumor was previously classified either as encapsulated classic PTC if it had a nuclear score of 2--3 or as follicular adenoma with papillary hyperplasia if it had a nuclear score of 0 or 1 according to the WHO classification \[[@b3-jptm-2020-04-29]\]. However, the new diagnostic term "NEPRAS" can reclassify a subset of noninvasive encapsulated papillary-patterned tumors as borderline tumors \[[@b2-jptm-2020-04-29]\].

NEPRASs share common characteristics of NIFTP as a noninvasive encapsulated tumor, having *RAS*-like mutations, and demonstrating a PTC-type nuclear score of 2. However, NEPRAS lesions are papillary-patterned tumors and can have psammoma bodies ([Fig. 1](#f1-jptm-2020-04-29){ref-type="fig"}). Because the presence of true papillae and psammoma bodies suggest the probability of classic PTC, these findings are major exclusion criteria for the diagnosis of NIFTP. A nuclear score of 3 and the well-developed nuclear features of PTC are not exclusion criteria for NIFTP, but they indicate a higher probability of classic PTC and should serve as an indicator for a more thorough examination of the tumor, including more grossing and immunostaining or molecular testing for *BRAF* V600E ([Fig. 3](#f3-jptm-2020-04-29){ref-type="fig"}) \[[@b15-jptm-2020-04-29]-[@b18-jptm-2020-04-29]\]. As encapsulated papillary-patterned tumors with nuclear scores of 3 are frequently positive for the *BRAF* V600E mutation and therefore confidently diagnosed as PTC, a nuclear score of 3 is an exclusion criterion for diagnosis of NEPRAS. While NEPRAS remains a morphologic diagnosis like NIFTP, detection of *RAS*-like low-risk mutations (*RAS*, *BRAF* *K601E, EIF1AX, PPARG*fusion, *THADA* fusion, and so forth) further substantiates the diagnosis when molecular results are available. *BRAF*-like mutations (*BRAF* V600E, *ALK, RET/PTC, NTRK*fusions, etc.) and high-risk mutations (*TERT* promoter, *TP53, PIK3CA, CTNNB1*, etc.) are essentially exclusionary criteria for diagnosis of NEPRAS and NIFTP lesions. In our case series ([Table 2](#t2-jptm-2020-04-29){ref-type="table"}), one NEPRAS tumor had a KRAS mutation. In addition, the NRAS mutation was found in one NEPRAS tumor showing minimal capsular invasion. Another case had no *RAS* mutations.

Most encapsulated thyroid tumors without invasion are very indolent and behave like follicular adenoma despite their growth patterns. The management strategy for patients with NEPRAS tumors is similar to those with NIFTP lesions. Thyroid lobectomy is a sufficient treatment for NEPRAS and NIFTP tumors. No further surgery, completion thyroidectomy, or radioactive iodine treatment is required after surgical resection of the primary tumor. Thus, reclassification of a subset of encapsulated classic PTCs into borderline tumors would ultimately lead to more conservative treatment standard and improved quality of life for patients with these tumors.

NEPRAS tumors can progress to invasive cancer just as NIFTP has the potential to progress to an invasive encapsulated follicular variant of PTC ([Fig. 4](#f4-jptm-2020-04-29){ref-type="fig"}). When NIFTP and NEPRAS tumors develop capsular and/or vascular invasion, they are truly malignant and mostly labelled as PTCs based on the PTC-type nuclear features ([Table 1](#t1-jptm-2020-04-29){ref-type="table"}). However, the same cases may be diagnosed as follicular carcinoma if the nuclear features are interpreted as a nuclear score of 1. Fortunately, these tumors are lowrisk cancers despite their name and do not require additional treatment after surgical resection if the tumor is only minimally invasive without angioinvasion. [Table 2](#t2-jptm-2020-04-29){ref-type="table"} summarizes the reported cases in the literature, including our cases.

Although long-term follow-up results of patients with NEPRAS are not available, it is reasonable to expect an excellent outcome after surgical resection of the tumor. Even when late recurrences do occur, the disease can be successfully treated. While reclassification has important impacts in clinical practice, implementation of new diagnostic criteria and terminologies may provoke resistance in pathologists and clinicians at variable levels. However, these efforts by pathologists will contribute to reducing the incidence rates of overdiagnosis and overtreatment of thyroid cancer.
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![Noninvasive encapsulated papillary *RAS*-like thyroid tumor. (A) The tumor has a thick fibrous capsule and shows cystic change. (B) The solid area is predominantly composed of papillary architecture lined by cuboidal to columnar follicular cells. (C) Psammoma bodies are occasionally seen (arrow). (D) Tumor cells show nuclear enlargement, overlapping, and elongation, with slightly irregular nuclear membranes and dark chromatin, and have no nuclear pseudoinclusions. Molecular analysis revealed *KRAS* G12V mutation.](jptm-2020-04-29f1){#f1-jptm-2020-04-29}

![Follicular adenoma with papillary hyperplasia. The tumor is cystic and has a thick complete capsule upon gross (A) and microscopic examination (B). (C) The tumor is composed of a predominantly papillary structure. (D) Tumor cells show basally located, small, and dark nuclei with round contours.](jptm-2020-04-29f2){#f2-jptm-2020-04-29}

![Noninvasive encapsulated classic papillary thyroid carcinoma with predominant follicular growth and *BRAF* V600E. This tumor was initially misdiagnosed as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). (A) The tumor is completely surrounded by a thin fibrotic capsule. (B) The encapsulated tumor is composed of follicular architecture. (C) The tumor cells have florid nuclear features of papillary carcinoma. Nuclear pseudoinclusions and grooves are frequently seen. (D) Immunostaining for *BRAF* V600E (VE1) is positive.](jptm-2020-04-29f3){#f3-jptm-2020-04-29}

![Two cases of the invasive form of noninvasive encapsulated papillary *RAS*-like thyroid tumor. (A, B) A tumor with *NRAS* Q61R. (C, D) The other case without *BRAF* V600E or RAS mutations. Both tumors show capsular invasion (A, C). A high-power view of the tumors reveals enlarged round-to-ovoid, overlapping nuclei with few nuclear grooves and less chromatin clearing than seen in classic papillary carcinoma.](jptm-2020-04-29f4){#f4-jptm-2020-04-29}

###### 

Classification of encapsulated thyroid tumors with *RAS*-like mutations: a proposal for NEPRAS

  Tumor behavior   Invasion       Nuclear score^[a](#tfn1-jptm-2020-04-29){ref-type="table-fn"}^   Papillary architecture                                                                 Predominantly follicular growth                                 
  ---------------- -------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------
  Benign           Absent         0 to 1                                                           Follicular adenoma with papillary hyperplasia                                          Follicular adenoma, conventional type                           Follicular adenoma, conventional type
  Borderline       Absent         2 (rarely 3)                                                     NEPRAS                                                                                 \-                                                              NIFTP
  Questionable     2 (rarely 3)   \-                                                               \-                                                                                     WDT-UMP                                                         
  Malignant        Present        1 (rarely 0)                                                     Follicular carcinoma                                                                   Follicular carcinoma                                            Follicular carcinoma
  Present          2 to 3         Papillary carcinoma, encapsulated classic variant                Papillary carcinoma, encapsulated classic variant with predominant follicular growth   Papillary carcinoma, invasive encapsulated follicular variant   

NEPRAS, noninvasive encapsulated papillary RAS-like thyroid tumor; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; WDTUMP, well-differentiated tumor of uncertain malignant potential.

Nuclear score is calculated as the sum of all categories of nuclear features of papillary carcinoma: (1) nuclear size and shape (nuclear enlargement, overlapping, crowding, and elongation), (2) nuclear membrane irregularities (irregular nuclear contours, grooves, and pseudoinclusions), (3) chromatin characteristics (chromatin clearing, margination of chromatin to the membrane, glassy nuclei) \[[@b14-jptm-2020-04-29]\].

###### 

Cases of noninvasive encapsulated papillary *RAS*-like thyroid tumor and its malignant counterpart with invasion

  Reference                                                  Age (yr)   Sex   FNA category^[a](#tfn2-jptm-2020-04-29){ref-type="table-fn"}^   Size (cm)   Invasion   Nuclear score   Papillary component   Cystic change   Psammoma bodies    Molecular profile                                                     Immunohistochemistry
  ---------------------------------------------------------- ---------- ----- --------------------------------------------------------------- ----------- ---------- --------------- --------------------- --------------- ------------------ --------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Index case, Ohba et al. (2019) \[[@b2-jptm-2020-04-29]\]   26         M     II, IV                                                          2.3         Absent     2               Dominant              Present         Present            *KRAS* G12A; *BRAF*, *NRAS*, *HRAS*, and *TERT* promoter: wild type   Ki-67 index 1%--2%
  Rosario (2020) \[[@b1-jptm-2020-04-29]\]                   35         F     IV                                                              4.0         Absent     2               \< 1%                 NA              NA                 *BRAF* wild type                                                      
  43                                                         F          III   2.2                                                             Absent      2          1%              NA                    NA              *BRAF* wild type                                                                         
  48                                                         M          IV    3.5                                                             Absent      2          1%              NA                    NA              *BRAF* wild type                                                                         
  Case 1                                                     9          M     V                                                               3.7         Absent     2               Dominant              Present         Present            *KRAS* G12V; *BRAF* and **NRAS*:* wild type                           CK19, focal +; HBME1, focal +; CD56, focal loss; ALK, negative; Pan-Trk, negative
  Case 2                                                     38         M     III                                                             1.2         Capsular   2               Dominant              Present         Absent             *NRAS* Q61R; *BRAF*, *HRAS*, *KRAS*, and *TERT* promoter: wild type   
  Case 3                                                     21         M     II                                                              4.0         Capsular   2               Dominant              Present         Absent             *BRAF*, *NRAS*, *HRAS*, and *KRAS*: wild type                         

FNA, fine-needle aspiration cytology; M, male; F, female; NA, not available.

Based on the categories of the Bethesda System for Reporting Thyroid Cytopathology.
